Lack of somatic mutations in EGFR tyrosine kinase domain in hepatocellular and nasopharyngeal carcinoma

Abstract excerpt

Activating EGFR somatic mutations have been shown to predict treatment response to small molecules targeting the EGFR intracellular tyrosine kinase domain. Recent work on cell-lines and animal models had demonstrated an inhibitory effect of EGFR tyrosine kinase inhibitors in hepatocellular and nasopharyngeal carcinoma, and clinical trials in these tumour types are ongoing. There are few data on the presence or...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Colorectal Cancer Treatments and Studies
• Share to HER2/EGFR in Cancer Research
• Share to Lung Cancer Treatments and Mutations